Research ExplorerPublicationsPotential Explanations for Increasing Methylphenidate Use in...

Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013

Standard

Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013. / Langner, Ingo; Haug, Ulrike; Scholle, Oliver; Lindemann, Christina; Schröder, Carsten; Riedel, Oliver.

In: Journal of clinical psychopharmacology, Vol. 39, No. 1, 2019, p. 39-45.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Langner, I, Haug, U, Scholle, O, Lindemann, C, Schröder, C & Riedel, O 2019, 'Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013', Journal of clinical psychopharmacology, vol. 39, no. 1, pp. 39-45. https://doi.org/10.1097/JCP.0000000000000980

APA

Langner, I., Haug, U., Scholle, O., Lindemann, C., Schröder, C., & Riedel, O. (2019). Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013. Journal of clinical psychopharmacology, 39(1), 39-45. https://doi.org/10.1097/JCP.0000000000000980

Vancouver

Langner I, Haug U, Scholle O, Lindemann C, Schröder C, Riedel O. Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013. Journal of clinical psychopharmacology. 2019;39(1):39-45. https://doi.org/10.1097/JCP.0000000000000980

Bibtex

@article{8b68115e51124a84b5f1d7e48101c577,
title = "Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013",
abstract = "BACKGROUND: Despite a decreasing population of children and adolescents, the cumulative total amount of dispensed methylphenidate (MPH), the first-choice treatment of attention-deficit/hyperactivity disorder (ADHD) in this age group, has increased dramatically in Germany. We investigated potential reasons for this increase such as changes in the ADHD prevalence over time and other potential explanations including the cumulative amount of dispensed MPH per person.METHODS: Based on German claims data, we calculated standardized annual ADHD prevalence rates, proportions of ADHD cases treated with MPH and/or psychotherapy, and mean cumulative defined daily doses of ADHD drugs for 3- to 17-year-old children and adolescents from 2004 to 2013.RESULTS: The ADHD prevalence increased continuously from 2004 to 2011 and remained stable thereafter. In ADHD cases, there was little variation in the proportion of individuals treated with drugs and in the frequency of psychotherapeutic treatment during the whole study period. The annual cumulative mean amount of MPH defined daily doses increased by approximately 30% from 2004 to 2008.CONCLUSIONS: Our analyses suggest that the increase in MPH use in Germany was mainly influenced by an increasing ADHD prevalence and increasing amounts of dispensed MPH per person.",
keywords = "Adolescent, Attention Deficit Disorder with Hyperactivity/drug therapy, Central Nervous System Stimulants/therapeutic use, Child, Child, Preschool, Delayed-Action Preparations/therapeutic use, Dose-Response Relationship, Drug, Drug Utilization/statistics & numerical data, Female, Germany/epidemiology, Humans, Male, Methylphenidate/therapeutic use, Prevalence, Psychotherapy/statistics & numerical data",
author = "Ingo Langner and Ulrike Haug and Oliver Scholle and Christina Lindemann and Carsten Schr{\"o}der and Oliver Riedel",
year = "2019",
doi = "10.1097/JCP.0000000000000980",
language = "English",
volume = "39",
pages = "39--45",
journal = "J CLIN PSYCHOPHARM",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013

AU - Langner, Ingo

AU - Haug, Ulrike

AU - Scholle, Oliver

AU - Lindemann, Christina

AU - Schröder, Carsten

AU - Riedel, Oliver

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Despite a decreasing population of children and adolescents, the cumulative total amount of dispensed methylphenidate (MPH), the first-choice treatment of attention-deficit/hyperactivity disorder (ADHD) in this age group, has increased dramatically in Germany. We investigated potential reasons for this increase such as changes in the ADHD prevalence over time and other potential explanations including the cumulative amount of dispensed MPH per person.METHODS: Based on German claims data, we calculated standardized annual ADHD prevalence rates, proportions of ADHD cases treated with MPH and/or psychotherapy, and mean cumulative defined daily doses of ADHD drugs for 3- to 17-year-old children and adolescents from 2004 to 2013.RESULTS: The ADHD prevalence increased continuously from 2004 to 2011 and remained stable thereafter. In ADHD cases, there was little variation in the proportion of individuals treated with drugs and in the frequency of psychotherapeutic treatment during the whole study period. The annual cumulative mean amount of MPH defined daily doses increased by approximately 30% from 2004 to 2008.CONCLUSIONS: Our analyses suggest that the increase in MPH use in Germany was mainly influenced by an increasing ADHD prevalence and increasing amounts of dispensed MPH per person.

AB - BACKGROUND: Despite a decreasing population of children and adolescents, the cumulative total amount of dispensed methylphenidate (MPH), the first-choice treatment of attention-deficit/hyperactivity disorder (ADHD) in this age group, has increased dramatically in Germany. We investigated potential reasons for this increase such as changes in the ADHD prevalence over time and other potential explanations including the cumulative amount of dispensed MPH per person.METHODS: Based on German claims data, we calculated standardized annual ADHD prevalence rates, proportions of ADHD cases treated with MPH and/or psychotherapy, and mean cumulative defined daily doses of ADHD drugs for 3- to 17-year-old children and adolescents from 2004 to 2013.RESULTS: The ADHD prevalence increased continuously from 2004 to 2011 and remained stable thereafter. In ADHD cases, there was little variation in the proportion of individuals treated with drugs and in the frequency of psychotherapeutic treatment during the whole study period. The annual cumulative mean amount of MPH defined daily doses increased by approximately 30% from 2004 to 2008.CONCLUSIONS: Our analyses suggest that the increase in MPH use in Germany was mainly influenced by an increasing ADHD prevalence and increasing amounts of dispensed MPH per person.

KW - Adolescent

KW - Attention Deficit Disorder with Hyperactivity/drug therapy

KW - Central Nervous System Stimulants/therapeutic use

KW - Child

KW - Child, Preschool

KW - Delayed-Action Preparations/therapeutic use

KW - Dose-Response Relationship, Drug

KW - Drug Utilization/statistics & numerical data

KW - Female

KW - Germany/epidemiology

KW - Humans

KW - Male

KW - Methylphenidate/therapeutic use

KW - Prevalence

KW - Psychotherapy/statistics & numerical data

U2 - 10.1097/JCP.0000000000000980

DO - 10.1097/JCP.0000000000000980

M3 - SCORING: Journal article

C2 - 30489381

VL - 39

SP - 39

EP - 45

JO - J CLIN PSYCHOPHARM

JF - J CLIN PSYCHOPHARM

SN - 0271-0749

IS - 1

ER -